Overview

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Status:
Completed

Trial end date:
2013-03-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether the MEK inhibitor and the AKT inhibitor can be given in combination and if the combination is effective treatment for patients with solid tumors, including breast cancer and endometrial cancer, and for patients with multiple myeloma.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Trametinib